Form 4: Atara Biotherapeutics Officer Sells Shares for Tax

Atara Biotherapeutics' Chief Accounting Officer, Yanina Grant-Huerta, sold common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Chief Accounting Officer Yanina Grant-Huerta reported sales of Atara Biotherapeutics common stock.
• The transactions occurred on March 2, 2026.
• A total of 2,104 shares were sold across four separate transactions at prices ranging from $5.077 to $5.083 per share.
• These sales were non-discretionary, executed automatically to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units.
• Following these transactions, Ms. Grant-Huerta beneficially owns 31,750 shares of common stock.
• This amount includes 400 shares purchased under the company's Employee Stock Purchase Plan on November 28, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales are non-discretionary and solely for tax purposes, which is a standard practice for equity compensation.

Positives

• The sales were non-discretionary, solely for tax withholding purposes, indicating no change in management's confidence in the company.
• The Chief Accounting Officer retains a significant beneficial ownership of 31,750 shares after the transactions.

Negatives

• The officer's direct beneficial ownership of common stock decreased by 2,104 shares due to the sales.

Future Outlook

No forward-looking statements or guidance are provided in this transactional filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. These specific sales are for tax purposes, which is a common practice for executives receiving equity compensation, and typically do not signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders may note a slight reduction in insider holdings, but the non-discretionary nature of the sales for tax purposes mitigates concerns about management's confidence.

Key Dates

Recommendation

The reported transactions are routine, non-discretionary sales by an officer to cover tax obligations associated with restricted stock unit vesting. Such sales do not typically reflect a change in the officer's confidence in the company's future or warrant a change in investment recommendation. The officer retains a substantial holding.

Keywords

Atara Biotherapeutics, ATRA, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU, Chief Accounting Officer